LIFECORE BIOMEDICAL, INC. Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
LIFECORE BIOMEDICAL, INC. (LFCR) reported Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities of $0 for the 12-month period ending 2020-05-31, per its 10-K filed 2020-08-14.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities · last filed 2020-08-14
- LIFECORE BIOMEDICAL, INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2020 was $0.00.
- LIFECORE BIOMEDICAL, INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- LIFECORE BIOMEDICAL, INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2018 was $95.00K.
- LIFECORE BIOMEDICAL, INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2017 was $0.00.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month |
|---|---|
| 2020-05-31 | $0.00 10-K · filed 2020-08-14 |
| 2019-05-26 | $0.00 10-K · filed 2020-08-14 |
| 2018-05-27 | $95.00K 10-K · filed 2020-08-14 |
| 2017-05-28 | $0.00 10-K · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |